Estrogen receptor status in inflammatory breast carcinoma.
Sixteen women with a clinical diagnosis of inflammatory breast carcinoma had estrogen receptor analysis performed. Eleven of 16 were premenopausal. Median age of all patients was 46 years. All patients had estrogen receptor (ER) assay by either dextran charcoal method or by sucrose gradient method. Five patients were ER + ( greater than or equal to 10 fmol/mg cytosol protein) and 11 were ER -, with almost no binding at all. Response to therapy for metastatic disease using either hormones or chemotherapy was disappointing.
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000032:analysis / Q000188:drug therapy* / Q000601:surgery; D002277:Carcinoma / Q000032:analysis / Q000188:drug therapy* / Q000601:surgery; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D011379:Prognosis; D011960:Receptors, Estrogen / Q000032:analysis*; D044465:White People
D000970:Antineoplastic Agents; D011960:Receptors, Estrogen; D004317:Doxorubicin; D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate